Goldman Sachs
ARTV

Goldman Sachs’s Artiva Biotherapeutics ARTV Stock Holding History

Goldman Sachs’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.8K Sell
11,465
-595
-5% -$2.94K ﹤0.01% 6247
2025
Q4 		$51.7K Sell
12,060
-37,717
-76% -$142K ﹤0.01% 6284
2025
Q3 		$143K Sell
49,777
-68,226
-58% -$183K ﹤0.01% 6014
2025
Q2 		$178K Buy
118,003
+76,051
+181% +$160K ﹤0.01% 5692
2025
Q1 		$126K Buy
41,952
+3,882
+10% +$21K ﹤0.01% 5740
2024
Q4 		$384K Buy
38,070
+8,523
+29% +$102K ﹤0.01% 5384
2024
Q3 		$457K Buy
+29,547
New +$342K ﹤0.01% 5098

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Goldman Sachs's ARTV Position: Q1 2026 in Review

Goldman Sachs reduced its Artiva Biotherapeutics (ARTV) stake by 4.9% in Q1 2026, selling an estimated $2.94K and leaving 11,465 shares worth $73.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6247.

Goldman Sachs first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $457K in Q3 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Goldman Sachs held 11,465 shares of Artiva Biotherapeutics worth $73.8K as of Q1 2026.
  • Goldman Sachs sold 595 Artiva Biotherapeutics shares in Q1 2026, an estimated $2.94K.
  • Artiva Biotherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6247 holding.
  • Goldman Sachs first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • Goldman Sachs's Artiva Biotherapeutics position peaked at $457K in Q3 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.